Vitiligo is a chronic depigmenting disorder whose impact extends beyond visible changes in skin color. For patients, white patches on the face, hands, or other body areas may affect self-confidence, social interaction, clothing choices, interpersonal relationships, productivity, and healthcare-related expenditures, including those for consultations, medications, phototherapy, and camouflage cosmetics. Current evidence identifies vitiligo primarily as an autoimmune disease arising from interactions among genetic susceptibility, oxidative stress of the melanocyte, activation of the innate immunity, autoreactive CD8+ T cells, and the interferon-gamma-JAK-STAT-CXCL9/CXCL10 axis. The diagnosis of vitiligo is generally established clinically and may be supported by Wood’s lamp examination. However, when determining treatment strategy, it is essential to assess disease activity, the extent and anatomical distribution of the lesions, leukotrichia, the presence of Koebner phenomenon or concomitant autoimmune disorders, and patient’s psychosocial burden. Topical corticosteroids, calcineurin inhibitors, narrow-band ultraviolet B phototherapy, topical Janus kinase (JAK) inhibitors, and systemic therapies in appropriate patients are major components of contemporary care. Topical ruxolitinib introduced a targeted, locally acting therapeutic strategy based on the underlying pathophysiology of the disease, mechanism-directedtherapy into routine vitiligo treatment, whereas oral upadacitinib received European Union authorization in July 2026 for use in nonsegmental vitiligo, further extending the targeted-therapy approach to systemic treatment. Modern management is therefore evolving from an approach focused solely on repigmentation toward long-term disease control that integrates autoimmune activity, melanocyte regenerative capacity, relapse prevention, safety, and the patient’s lived experience.
Copyrights © 2026